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Abstract
Background: Uncontrolled cytomegalovirus (CMV) replication in immunocompromised solid-organ transplant
recipients is a clinically relevant issue and an indication of impaired CMV-specific cell-mediated immunity (CMI).
Primary aim of this study was to assess the suitability of the immune monitoring tool T-Track® CMV to determine
CMV-reactive CMI in a cohort of hemodialysis patients representative of patients eligible for renal transplantation.
Positive and negative agreement of T-Track® CMV with CMV serology was examined in 124 hemodialysis patients,
of whom 67 (54%) revealed a positive CMV serostatus. Secondary aim of the study was to evaluate T-Track® CMV
performance against two unrelated CMV-specific CMI monitoring assays, QuantiFERON®-CMV and a cocktail of six
class I iTAg™ MHC Tetramers.
Results: Positive T-Track® CMV results were obtained in 90% (60/67) of CMV-seropositive hemodialysis patients. In
comparison, 73% (45/62) and 77% (40/52) positive agreement with CMV serology was achieved using
QuantiFERON®-CMV and iTAg™ MHC Tetramer. Positive T-Track® CMV responses in CMV-seropositive patients were
dominated by pp65-reactive cells (58/67 [87%]), while IE-1-responsive cells contributed to an improved (87% to
90%) positive agreement of T-Track® CMV with CMV serology. Interestingly, T-Track® CMV, QuantiFERON®-CMV and
iTAg™ MHC Tetramers showed 79% (45/57), 87% (48/55) and 93% (42/45) negative agreement with serology,
respectively, and a strong inter-assay variability. Notably, T-Track® CMV was able to detect IE-1-reactive cells in blood
samples of patients with a negative CMV serology, suggesting either a previous exposure to CMV that yielded a
cellular but no humoral immune response, or TCR cross-reactivity with foreign antigens, both suggesting a possible
protective immunity against CMV in these patients.
Conclusion: T-Track® CMV is a highly sensitive assay, enabling the functional assessment of CMV-responsive cells in
hemodialysis patients prior to renal transplantation. T-Track® CMV thus represents a valuable immune monitoring
tool to identify candidate transplant recipients potentially at increased risk for CMV-related clinical complications.
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Background
Cytomegalovirus (CMV) is a major cause of infectious
complications in immunocompromised individuals. Pro-
tection against CMV infection or reactivation is nor-
mally assured by both the innate and adaptive arms of
the immune system [1, 2]. While the humoral and innate
responses are essential for the early response to infection
[1, 3, 4], cellular immunity is required to control latency
and prevent CMV reactivation in latently infected indi-
viduals [1]. CD8+ cytotoxic T cells (CTL) and CD4+ T
helper (Th) cells are both required to assure efficient
immune protection against CMV reactivation [1, 5–8].
Primary infection is dominated by CD8+ T cell response,
preferentially targeting CMV immediate early-1 (IE-1)
antigen, while long-term recovery is dominated by CD4+
T cell response and a switch of reactivity toward CMV
lower matrix phosphoprotein 65 (pp65) [6, 8–11]. The
frequency of CMV-specific CD8+ and CD4+ T cells is
highly variable, both between healthy CMV-seropositive in-
dividuals and during the course of CMV reactivation, and
correlates with varying levels of protection [6, 9, 11–13].
Beside changes in T cell frequency, alterations in T cell
functionality are associated with impaired response to
chronic viral infection [14–17].
Functional impairment of cell-mediated immunity
(CMI) in the course of immunosuppression, such as in
solid-organ transplant recipients, is a major cause of
uncontrolled CMV replication and related clinical com-
plications [18–21]. Treatment regimens with antivirals
are costly and associated with harmful side effects.
Assessment of CMV-specific immunity may be beneficial
to identify patients at increased risk of viral complica-
tions, possibly allowing personalized adjustment of anti-
viral and immunosuppressive therapies.
Various experimental approaches exist to measure
CMV-specific CMI. Direct T cell staining with for in-
stance class I iTAg™ MHC Tetramers (Beckman Coulter)
allows the quantification of epitope-specific CD8+ cells
by flow cytometry [18, 22–24]. The sensitivity of
tetramer-based assays strictly depends on the coverage
of the patient population by the selected HLA types, and
this method cannot assess the functionality of CD8+
cells. Several assays assessing CMV-specific T cell func-
tion have been described. Principally, they measure the
production of activation markers (e.g. cytokines such as
IFN-γ) in response to antigen stimulation, using intra-
cellular cytokine staining followed by flow cytometry
[6, 7, 12, 13, 25, 26], ELISA [21, 27–30], or ELISpot
[31–33] assays. These approaches differ not only in
their read-out format but also in the antigen (peptide vs.
protein) used for the ex vivo stimulation. Peptide-based
immune monitoring tests such as QuantiFERON®-CMV
(Qiagen) allow the quantification of IFN-γ produced by
epitope-specific CD8+ T cells. Whole blood samples are
stimulated with a pool of 22 immunogenic peptides
(mapping at IE-1, IE-2, pp28, pp50, pp65 and gB CMV
antigens) and covering > 98% of HLA class-I haplotypes.
Reactive CD8+ T cells are monitored by quantifying
secreted IFN-γ by ELISA [34]. QuantiFERON®-CMV was
used in a number of studies to assess the risk of CMV
reactivation and related disease following solid-organ
transplantation [21, 27–30]. A disadvantage of Quanti-
FERON®-CMV is that it does not assess CMV-specific
CD4+ T cell function and that it often yields indeterminate
results that cannot be interpreted [28, 35, 36]. T-Track®
CMV is based on the stimulation of freshly isolated
peripheral blood mononuclear cells (PBMC) with recom-
binant urea-formulated (T-activated®) immunodominant
CMV IE-1 and pp65 proteins, and the subsequent quanti-
fication of antigen-reactive effector cells using an IFN-γ
ELISpot assay. T-activated® proteins (aproteins) are
processed via the exogenous and endogenous antigen
processing pathways, resulting in the presentation of
naturally-generated peptides by MHC class I and class
II molecules, thus enabling the stimulation of a broad
spectrum of CMV-protective cells including CD8+ and
CD4+ T cells, as well as the bystander activation of NK and
NKT-like cells [37, 38]. As such, T-Track® CMV is not re-
stricted to particular HLA types. Performance of T-Track®
CMV has been recently characterized [38]. A recent study
demonstrated its high sensitivity in evaluating changes in
CMV-specific CMI during and after pregnancy [39].
Primary aim of this cross-sectional prospective multi-
center study was to evaluate the suitability of T-Track®
CMV to assess the functionality of CMV-specific CMI in
a cohort of patients on hemodialysis due to end-stage
renal failure, and thus being representative of patients
prior to renal transplantation. Secondary aim of the
study was to compare the performance of T-Track®
CMV to that of QuantiFERON®-CMV and iTAg™ MHC
Tetramers in terms of positive and negative agreement
with CMV serology (gold standard reference).
Methods
Study design and participants
Hemodialysis patients of any gender and race aged at
least 18 years were recruited in the study. Patients
requiring systemic immunosuppressive treatment within
the last 3 months before study inclusion or suffering
from chronic or uncontrolled infections (e.g. HIV or
chronic hepatitis) were ineligible for study participation.
All subjects gave written informed consent. The study
was registered and approved according to the rules, at
the German Institute of Medical Documentation and
Information (DIMDI). Patient enrolment was started
only after receiving the exemption of the permit require-
ment by the BfArM (Federal Institute for Drugs and
Medical Devices) and approval by the ethics committee
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of the University of Regensburg (approval number 11-
122-0205). For reasons of transparency and complete-
ness, the study was prospectively registered at clinical-
trials.gov. The authors confirm that all ongoing and
related trials for this intervention are registered at
clinicaltrials.gov.
Blood collection
Lithium heparinized whole blood was collected during
routine withdrawal, prior to the start of the dialysis ses-
sion. For T-Track® CMV and iTAg™ MHC Tetramer
staining, 15 ml blood was collected for further PBMC
isolation. For QuantiFERON®-CMV, 0.8 to 1.2 ml whole
blood was collected into each of the three assay tubes.
CMV serology was performed from 2.6 ml whole blood.
CMV serology
Anti-CMV serological testing was performed using fully
automated anti-CMV IgM and IgG tests on the BEP III
system (Siemens Healthcare, Eschborn, Germany). CMV
IgG-serology was used as primary reference measure-
ment procedure (gold standard method).
CMV-specific cellular immunity assays
T-Track® CMV (Lophius Biosciences GmbH, Regensburg,
Germany) was performed according to manufacturer’s
instructions. Briefly, PBMC were isolated and stimulated
individually with T-activated® CMV-specific immediate-
early 1 (aIE-1) and phosphoprotein pp65 (app65) proteins
for 19 h at 37°C. Staphylococcus enterotoxin B (SEB) and
medium served as positive and negative controls for the
stimulation, respectively. IFN-γ ELISpot assays were per-
formed following manufacturer’s recommendations. IFN-
γ-specific spot-forming cells (SFC) were enumerated on a
Bioreader® 5000 Pro-Eα (BIO-SYS GmbH, Karben,
Germany). Test results were considered positive if the
geometric mean of the spots resulting from at least
one of the app65 and aIE1 stimulations was ≥ 10
SFC/200,000 PBMC and when the ratio of the
geometric means of stimulated and non-stimulated
conditions was ≥ 2.5. Positivity rules were calculated
as described in the Statistics section.
The QuantiFERON®-CMV assay (Qiagen, Hilden,
Germany) was performed according to manufacturer’s in-
structions. Briefly, QuantiFERON®-CMV collection tubes
(Nil Control, CMV Antigen and Mitogen Control) were
incubated for 16–24 h at 37°C. IFN-γ levels were deter-
mined by enzyme-linked immunosorbent assay (ELISA).
Calculation of results was achieved using QuantiFERON®-
CMVAnalysis Software. QuantiFERON®-CMV test results
were considered positive when IFN-γ level (IU/mL) in the
CMVAntigen-specific assay minus that in the Nil Control
was ≥ 0.2, as recommended by the manufacturer. ELISA
measurements are accurate up to 10 IU/mL. Values ≥ 10
IU/mL cannot be quantitatively evaluated.
For the CMV-specific tetramer assay, CMV peptide-
specific CD8+ T cells were quantified by flow cytometry
using a mixture of six class I iTAg™ MHC Tetramers
(Beckman Coulter), including: MHC A*0101 Class I
Tetramer CMV pp50 (VTEHDTLLY), MHC A*0201 Class
I Tetramer CMV pp65 (NLVPMVATV), MHC A*2402
Class I Tetramer CMV pp65 (QYDPVAALF), MHC
B*0702 Class I Tetramer CMV pp65 (TPRVTGGGAM),
MHC B*0801 Class I Tetramer CMV IE-1 (ELRRKM-
MYM) and MHC B*3501 Class I Tetramer CMV pp65
(IPSINVHHY). iTAg™ MHC Negative Tetramer PN
T01044 (Beckman Coulter) served as negative control.
Preselected HLA types are predicted to cover at least 80%
of the Caucasian population [40]. Each 1×106 PBMC were
stained with 10 μl tetramer mix, 10 μl anti-CD8-FITC
(T8-FITC, Beckman Coulter) and 5 μl human CD3 APC-
Alexa Fluor® 750 conjugate (Invitrogen/Thermo Fisher
Scientific) for 30 min at room temperature protected from
light. Cells were washed once in PBS and incubated 45
min at 4 °C protected from light. Dead cells were further
stained with SYTOX® RED dead cell stain (Invitrogen/
Thermo Fisher Scientific) for 15 min at 4 °C protected
from light, prior to flow cytometry analysis. Measure-
ments were performed using a Cytomics FC 500 MPL
cytometer (Beckmann Coulter), gating on living and CD3-
positive cells. Cell count from the iTAg™ MHC Tetramer
Negative staining was subtracted from that of the iTAg™
MHC Tetramer CMV-specific cocktail staining. Data were
expressed as the % of CMV-specific tetramer-positive CD8+
T cells relative to total CD8+ T cells. Test results were con-
sidered positive, when the proportion of tetramer-positive
CD8+ cells was ≥ 0.1% of total CD8+ T cells.
Statistics
Calculations were performed with SAS 9.2 Software and
VFP (Variance Function Program) 10.0. Figures were
generated using GraphPad Prism. In case of categorically
scaled data, absolute and relative frequencies were re-
ported. For continuously scaled data, mean, median,
geometric mean, standard deviation, minimum and
maximum have been reported. Diagnostic accuracies (sen-
sitivity and specificity) were analyzed from 2 × 2 contin-
gency tables referring bivariate test results to CMV
serostatus (reference method). Since the reference stand-
ard was not disease but a comparative method, the terms
“percent positive agreement” and “percent negative agree-
ment” were used instead of “sensitivity” and “specificity”
respectively. The measures are reported with their exact
Pearson-Clopper confidence intervals. Kappa (κ) accord-
ing to Altman and McNemar’s test were used to indicate
overall agreement and consistency of pairs of methods
respectively. Significance was accepted at p < 0.05.
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The cut-off of T-Track® CMV positivity was deter-
mined using z-statistics (α-level = 0.05) on log10-
transformed geometric mean values. Values = 0 were
replaced by values near detection limit, which was
assumed to be 0.5. Intra-assay standard deviation (SD)
of ELISpot measurements from the hemodialysis patient
cohort (n = 124) and from a cohort of healthy donors
(n = 45; [38]) was calculated. SD was for the unstimu-
lated control, IE-1 stimulation and pp65 stimulation
0.199, 0.240 and 0.220 (hemodialysis patients), and
0.234, 0.192 and 0.136 (healthy donors), respectively.
Considering an intra-assay SD of 0.2 and assuming
that 4 replicates are measured for each negative con-
trol and test samples, a criterion that the ratio of
geometric means of stimulated to unstimulated values
is at least 2.5 was obtained. In addition, precision
profiles were generated from both IE-1- and pp65-
specific test results, whereby a coefficient of variation
(CV) no higher than 40% was used as a limit of ac-
ceptance of assay validity to determine the respective
limit of quantitation (LoQ). Precision profiles for IE-1-
and pp65-specific T-Track® CMV yielded LoQ values of
7.8 and 8.3 respectively (see Additional file 1). Comparable
limits of quantitation were obtained from precision pro-
files generated from T-Track® CMV assays performed on
PBMC from healthy donors [38]. Based on these analyses,
a technical cut-off of 10 SFC/200,000 PBMC was chosen.
Altogether, T-Track® CMV test results were consid-
ered positive if the geometric mean of the spots
resulting from at least one of app65 and aIE1 stimu-
lations was ≥ 10 SFC/200,000 PBMC and if the ratio
of the geometric means of stimulated to non-
stimulated conditions was ≥ 2.5.
Results
Patient characteristics
One hunderd twenty-four hemodialysis patients (68
men, 56 women, mean age 65 ± 13 years) were enrolled
in this study. The mean duration of dialysis was 1,913
days (range 21 to 11,640 days). A positive CMV-IgG ser-
ostatus was measured in 67/124 (54%) of hemodialysis
patients (Table 1). Blood was collected before the start
of the dialysis session. Routine blood parameters and
inflammation markers are depicted in Table 1.
One hunderd twenty-four T-Track® CMV, 123 Quanti-
FERON®-CMV and 97 iTAg™ MHC Tetramer measure-
ments were carried out from whole-blood (QuantiFERON®-
CMV) or from freshly isolated PBMC (T-Track® CMV,
iTAg™ MHC Tetramers). Insufficient amount of blood and/
or PBMC did not allow the performance evaluation of all
tests for all 124 patients. CMV serology served as a primary
reference measurement procedure (gold standard reference)
in the performance study.
Performance of T-Track® CMV
Positive and negative agreement of T-Track® CMV with
CMV serology was investigated using PBMC samples
from 124 hemodialysis patients. 58 of the 67 CMV-
seropositive patients showed a positive response to
app65 (Table 2) with a median of 165 spot-forming cells
(SFC)/200,000 PBMC and a maximum of 1,040 SFC/
200,000 PBMC (Fig. 1a). 33 of the 67 CMV-seropositive
patients demonstrated an aIE-1-specific response in the
T-Track® CMV ELISpot assay, with a median of 9.7 SFC/
200,000 PBMC and a maximum of 696 SFC/200,000
PBMC (Table 2 and Fig. 1a). By taking into account the
outcome of both aIE-1 and app65 stimulations, T-
Track® CMV results were positive in 60 out of 67 CMV-
seropositive patients, corresponding to an overall posi-
tive agreement with CMV serology of 89.6% (Table 2).
Interestingly, 12 out of 57 (21.1%) study participants
who scored negative in a conventional serological assay
presented with CMV-reactive effector cells in T-Track®
CMV, equivalent to a negative agreement with CMV
serology of 78.9% (Table 3). With one exception, positive
T-Track® CMV results in CMV-seronegative patients
were observed in aIE-1-stimulated PBMC samples, and
were mostly associated with low spot counts (10.3–23.6
SFC/200,000 PBMC in 9 out 12 patients; Fig. 1a). Three
patients however exhibited higher spot counts (93.6–116.5
SFC/200,000 PBMC). In contrast, one app65-positive test
result with a spot count of 94 SFC/200,000 PBMC was
observed among the 57 CMV-seronegative patients
(Fig. 1a). Of note, this patient also showed a positive test
result for aIE-1, with 109.2 SFC/200,000 PBMC (Fig. 1a).
Table 1 Demographic and blood parameters of hemodialysis
patients
Age (years), mean ± SD (range) 65 ± 13 (26; 88)
Gender, N (%)
Male 68 (54.8%)
Female 56 (45.2%)
CMV serostatus, N (%)
Positive 67 (54%)
Negative 57 (46%)
Duration of dialysis (days), mean ± SD (range) 1,913 ± 2,079 (21; 11,640)
Blood count, mean ± SD (range)
Hemoglobin (g/dl) 11.3 ± 1.2 (7.8; 16.1)
Erythrocytes (Tpt/l) 3.7 ± 0.44 (2.5; 5.2)
Leukocytes (pt/nl) 7.5 ± 2.4 (3.0; 17.8)
Thrombocytes (Tsd/μl) 234 ± 65 (84; 426)
Inflammation marker, mean ± SD (range)
CRP (mg/l)a 9.7 ± 17.6 (1.0; 143.0)
Absolute number of PBMC x 106 / 15 ml
whole blood (mean ± SD (range)
13.5 ± 9.8 (3.2; 87.3)
aCRP values were available for 80 out of 124 patients
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These observations suggest that T-Track® CMV might
have the capacity to detect CMV-reactive cells resulting
from a previous CMV infection that was however not
sufficient to yield an antibody response.
Performance of QuantiFERON®-CMV and iTAg™ MHC
Tetramers
The QuantiFERON®-CMV assay was performed on blood
samples from 66 CMV-seropositive and 57 CMV-
seronegative hemodialysis patients. QuantiFERON®-CMV
was positive (reactive) in 45/66, negative (non-reactive) in
17/66 and indeterminate in 4/66 of CMV-seropositive
patients. Conversely, 7/57, 48/57 and 2/57 of CMV-
seronegative patients showed positive, negative and inde-
terminate test results, respectively. Indeterminate results
were excluded from subsequent analyses, as a repetition of
the QuantiFERON®-CMV assay from fresh blood samples
was not possible. Thus, the results of the QuantiFERON®-
CMV assay revealed a positive and negative agreement
with CMV serology of 72.6% (45/62) and 87.3% (48/55)
respectively (Tables 2 and 3; Fig. 1b).
A mixture of six preselected CMV-specific class I
iTAg™ MHC Tetramers based on IE-1, pp65 and pp50
epitopes and predicted to cover at least 80% of the
Caucasian population was used to quantify the propor-
tion of CMV-specific CTL in freshly isolated PBMC of 52
CMV-seropositive and 45 CMV-seronegative hemodialysis
patients. In these experiments, 40/52 (76.9%) of CMV-
seropositive patients were test-positive with a median pro-
portion of 0.98% CMV-specific CD8+ T cells / total CD8+ T
Table 2 Positive agreement of T-Track® CMV, QuantiFERON®-CMV and iTAg™ MHC Tetramers with CMV serology in hemodialysis
patients
Test CMV positive serologya CMI+ CMI- Positive agreement 95% CI
T-Track® CMV 67 60 7 0.896 0.797–0.957
CMV aIE-1 67 33 34 0.493 0.368–0.618
CMV app65 67 58 9 0.866 0.760–0.937
QuantiFERON®-CMVb 62 45 17 0.726 0.598–0.831
iTAg™ MHC Tetramers 52 40 12 0.769 0.632–0.875
aCMV-serology served as primary reference measurement procedure; bcalculation of the positive agreement and associated 95% CI do not take into account the 4
indeterminate QuantiFERON®-CMV results out of the 66 CMV-seropositive patients; CMI+ positive test result, CMI- negative test result, CI confidence interval
Fig. 1 CMV-specific immunity in hemodialysis patients measured with T-Track® CMV (a), QuantiFERON®-CMV (b) and iTAg™ MHC Tetramers (c). a
Spot-forming cells (SFC) in IFN-γ ELISpot after in vitro stimulation of PBMC from CMV-seronegative (n = 57) and CMV-seropositive (n = 67)
hemodialysis patients with T-activated® aIE-1 and app65 proteins, or with medium (unst.) as a negative control. SFC levels are presented as
log10-transformed values in scatter plots, including median values (horizontal black lines). The horizontal grey dashed line indicates the positivity
cut-off (10 SFC / 200,000 PBMC). b CD8+-secreted IFN-γ levels were measured by ELISA following the stimulation of whole blood from CMV-
seronegative (n = 57) and CMV-seropositive (n = 66) hemodialysis patients with HLA class I-specific peptides. Test results were considered positive
when IFN-γ levels≥ 0.2 IU/mL (grey dashed line). Indeterminate results (4/66 seropositive and 2/57 seronegative patients) are not represented;
therefore the scatter plots represent the results of 62 seropositive and 55 seronegative assays. *, values≥ 10 IU/mL cannot be quantitatively
evaluated; consequently, no median values were depicted. c PBMC of CMV-seronegative (n = 45) and CMV-seropositive (n = 52) hemodialysis
patients were stained with a mixture of six iTAg™ MHC class I Tetramers, and CMV peptide-specific CD8+ T cells were quantified by flow
cytometry. Test results were considered positive when≥ 0.1% of total CD8+ T cells were tetramer-positive (grey dashed line). The scatter
plots show median values (horizontal black lines)
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cells and a maximum of 21.1% tetramer-positive
CD8+ T cells (Table 2 and Fig. 1c). Among 45 CMV-
seronegative patients 3 were assay-positive, correspond-
ing to a negative agreement with CMV-serology of 93.3%
(Table 3 and Fig. 1c).
Assessment of agreement between the different assays
The results of T-Track® CMV, QuantiFERON®-CMV and
iTAg™ MHC Tetramers were compared to assess their
level of agreement. Results of T-Track® CMV moderately
agreed with that of QuantiFERON®-CMV (κ = 0.445) and
of the CMV iTAg™ MHC Tetramers (κ = 0.434) (Table 4).
Statistical analysis of the number of discordant results be-
tween T-Track® CMV, QuantiFERON®-CMV and iTAg™
MHC Tetramers using the McNemar’s test revealed that
the consistency in the pairs of methods was statistically
different between T-Track® CMV and both Quanti-
FERON®-CMV (p = 0.0090) and iTAg™ MHC Tetramers
(p = 0.0082) (Table 4).
Notably, 14/17 and 12/12 CMV-seropositive patients
with negative results in QuantiFERON®-CMV and iTAg™
MHC Tetramer respectively, were assay-positive in T-
Track® CMV. Moreover, 5/5 CMV-seropositive patients
with negative results for both QuantiFERON®-CMV and
iTAg™ MHC Tetramers showed positive T-Track® CMV
results. Conversely, the 7 CMV-seropositive patients
with a negative T-Track® CMV result showed either posi-
tive or negative results by QuantiFERON®-CMV and
iTAg™ MHC Tetramers, revealing inter-assay discordance.
Interestingly, 3/4 CMV-seropositive patients with indeter-
minate QuantiFERON®-CMV results showed a positive T-
Track® CMV result, of which 2 were also CMV-Tetramer
positive. Finally, among the CMV-seronegative patients,
only 1 out of 12 positive T-Track® CMV assays was also
positive in QuantiFERON®-CMV while 6/7 and 3/3 posi-
tive results in QuantiFERON®-CMV and iTAg™ MHC
Tetramers respectively were negative in T-Track® CMV.
Discussion
T-Track® CMV represents a novel assay format, which
relies on the functional assessment of various CMV
protein-reactive effector cells, including CD4+ (Th) cells,
CD8+ (CTL), NK and NKT-like cells [37, 38], all of
which being described to contribute to the clearance of
CMV replication [1, 6–8, 41–44]. In this study, the suit-
ability of T-Track® CMV to measure CMV-specific CMI
in a cohort of dialysis patients and its performance
against QuantiFERON®-CMV [34] and iTAg™ MHC
Tetramer assays [24] were evaluated.
T-Track® CMV revealed a positive agreement with
CMV-serology of 90% in hemodialysis patients, higher
than that measured with QuantiFERON®-CMV (73%)
and a mixture of 6 preselected CMV-specific iTAg™
MHC Tetramers (77%), indicating a higher sensitivity of
T-Track® CMV compared to QuantiFERON®-CMV and
iTAg™ MHC Tetramers. This difference in positive
agreement with CMV-serology is likely due to the differ-
ence in format of the three assays. Beside the detection
of a broad repertoire of CD8+ T cells as a result of
antigen cross-presentation [37], T-Track® CMV is indeed
able to assess the functionality of CMV-reactive CD4+
cells but also the bystander activation of IFN-γ-
producing NK and NKT-like cells [41, 43–46]. In con-
trast, QuantiFERON®-CMV and iTAg™ MHC Tetramers
are restricted to the detection of selected CMV-specific
CD8+ cells. In addition to the assay format, the combin-
ation of results of the separate measurement of pp65-
and IE-1-responsive effector cells by T-Track® CMV con-
tributes to the increased positive agreement with CMV
serology, from 87% with pp65-specific CMI alone to 90%
with both pp65- and IE-1-specific CMI. This positive
contribution of IE-1 to the sensitivity of T-Track® CMV
is in agreement with the demonstration that CMV-
Table 3 Negative agreement of T-Track® CMV, QuantiFERON®-CMV and iTAg™ MHC Tetramers with CMV serology in hemodialysis
patients
Test CMV negative serologya CMI- CMI+ negative agreement 95% CI
T-Track® CMV 57 45 12 0.789 0.661–0.886
CMV aIE-1 57 45 12 0.789 0.661–0.886
CMV app65 57 56 1 0.982 0.906–1.000
QuantiFERON®-CMVb 55 48 7 0.873 0.755–0.947
iTAg™ MHC Tetramers 45 42 3 0.933 0.817–0.986
aCMV-serology served as primary reference measurement procedure; bcalculation of the negative agreement and associated 95% CI do not take into account the
2 indeterminate QuantiFERON®-CMV results out of the 57 CMV-seronegative patients; CMI- negative test result, CMI+ positive test result, CI confidence interval
Table 4 Assessment of strength (κ) and consistency (McNemar’s
Test) of agreement of T-Track® CMV results with QuantiFERON®-
CMV and iTAg™ MHC Tetramers results
Test 1 Test 2 κ 95% CI McNemar
T-Track® CMV QuantiFERON®-CMV 0.445 0.289–0.601 0.009
T-Track® CMV iTAg™ MHC Tetramers 0.434 0.264–0.604 0.008
According to Altman, kappa (κ) values between 0.4 and 0.6 refer to moderate
agreement. Consistency was evaluated by comparing the number of
discordant results using the McNemar’s Test (p < 0.05 was considered
statistically significant). Of note, assessment does not take into consideration
indeterminate results of the QuantiFERON®-CMV assay. CI confidence interval
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seropositive healthy donors do not always exhibit a
pp65-specific CD8+ T cell response and that a non-
negligible proportion of individuals only show a CD8+ T
cell response to IE-1 [47]. Other factors potentially en-
hancing the sensitivity of T-Track® CMV are the
standardization of the assay, which uses a constant num-
ber of PBMC (as opposed to whole blood in Quanti-
FERON®-CMV, possibly resulting in high inter-individual
variability), its HLA-type-independence (as opposed espe-
cially to the iTAg™ MHC Tetramer assay) and the absence
of indeterminate results (as opposed to QuantiFERON®-
CMV). In that regard, 4/66 CMV-seropositive and 2/57
CMV-seronegative hemodialysis patients yielded indeter-
minate results with QuantiFERON®-CMV, which - with a
rate of 5% - is lower than what was reported in transplant
recipients [28, 35, 36].
Interestingly, the positive agreement of T-Track® CMV
with CMV-serology of 90% measured in this cohort of
hemodialysis patients was lower than that obtained in
CMV-seropositive healthy individuals (97%; [38]). Simi-
larly, the positive agreement of QuantiFERON®-CMV
results with CMV-serology in hemodialysis patients
(73%) is below the positive agreement of 88% to 97%
previously reported in healthy adults [27, 34]. This dif-
ference might be explained by a functional impairment
of Th cells, CTL, Antigen-presenting cells (APC), NK
and NKT cells in patients with end-stage renal failure
undergoing hemodialysis [48–52]. A reduced CMV-CMI
prior to renal transplantation might be associated with
an increased risk of CMV reactivation following trans-
plantation. In support to this proposition, several studies
reported an association between impaired CMV-specific
CMI pre-transplantation and increased risk for CMV
viremia post-transplantation [29, 31, 53]. The high positive
agreement of T-Track® CMV with CMV serology observed
in this cohort of hemodialysis patients therefore empha-
sizes the suitability and clinical relevance of T-Track®
CMV for patients eligible for renal transplantation.
Although both CMV pp65 and IE-1 antigens contain
multiple CD4+ and CD8+ T cell epitopes presented by
different HLA alleles [40], the number of reactive ef-
fector cells responding to stimulation with app65 was
substantially higher than that responding to aIE-1. This
difference might result in part from the dynamics of
pp65- and IE-1-reactive CD4+ and CD8+ T cells in the
course of the immune response to CMV infection, long-
term seroconversion being dominated by pp65- over IE-
1-reactive T cells [8–11, 53, 54]. Moreover, mechanisms
of immune evasion involving CMV-encoded unique
short (US) proteins and resulting in the inhibition of the
MHC-I-dependent antigen presentation pathway appear
to be responsible for impaired IE-1 antigen processing
and presentation, and thus in the low frequency of IE-1-
reactive CD8+ T cells [55–57]. On the other hand,
differential antigen uptake, processing and presentation by
APC, possibly influenced by pp65 and IE-1 intrinsic prop-
erties [54, 58, 59], might explain inter-individual differences
in the frequency of CMV antigen-specific T cells. Accord-
ingly, comparable CD8+ T cell response to IE-1 and pp65
has also been described in some CMV-seropositive healthy
donors [47, 60]. The clinical significance of the differential
responses to different antigens using T-Track® CMV needs
to be elucidated in future studies.
12/57 CMV-seronegative patients revealed positive T-
Track® CMV results, corresponding to a negative agree-
ment of T-Track® CMV with CMV serology of 79%.
Positive test results were mainly attributed to aIE-1
stimulation, and negative agreement raised to 98% when
considering the results of app65 stimulation alone. IE-1-
induced spot counts were close to T-Track® CMV posi-
tivity threshold in 9/12 patients and only 3 CMV-
seronegative patients showed higher IE-1-induced spot
counts. We can reasonably rule out false negative CMV
serology test results in these patients, as repetition of
CMV serology 6 months upon completion of the study
in 9 patients who were still available, confirmed their
negative serostatus for IgG and IgM (data not shown).
Comparatively, 7/55 QuantiFERON®-CMV and 3/45 CMV
iTAg™ MHC Tetramer measurements also revealed positive
test results in seronegative dialysis patients. Interestingly,
with one exception, the 12, 7 and 3 CMV seronegative
patients with positive test results in T-Track® CMV, Quanti-
FERON®-CMV and CMV iTAg™ MHC Tetramers, respect-
ively, were different. This inter-assay variability contributes
to the moderate agreement (κ =~0.4) observed between T-
Track® CMV and the 2 alternative assays, and is in agree-
ment with previous studies reporting discordant results
between IFN-γ ELISpot and QuantiFERON®-CMV [61, 62].
This inter-assay variability likely reflects differences in the
ability of antigen stimulants in each assay to activate
distinct subsets of CMV-reactive T cells. Urea formulation
of T-activated® CMV antigens increases protein uptake and
promotes antigen processing and presentation in the
context of both MHC-I (cross-presentation) and
MHC-II [37]. T-Track® CMV is thus able to activate a
broad range of CD8+ and CD4+ T cells, encompassing
a larger T cell repertoire than QuantiFERON®-CMV
or iTAg™ MHC-I Tetramers, and possibly explaining
the higher number of CMV-seronegative patients with
positive T-Track® CMV test results.
Interestingly, detection of CMV-reactive effector T cells
within CMV-seronegative individuals has been described
by others, both in healthy individuals and in transplant re-
cipients, at frequencies of 2–11% among healthy donors
and up to 30% in renal transplant recipients [13, 63–65].
With 21% CMV-seronegative hemodialysis patients with
positive T-Track® CMV results, our data are in concord-
ance with these published studies. Although Sester et al.
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questioned the accuracy of serologic testing, in particular
in case of borderline immunoglobulin titers [65], Loeth
et al. elegantly demonstrated in their study on healthy
individuals, that the frequency of 11% seronegative donors
with pp65-specific CD4+ and CD8+ response was neither
due to wrong serological assignment, nor to immune
cross-reactivity with the closely related herpes virus
HHV6, nor to in vitro priming. Instead, their demonstra-
tion that a large proportion of seronegative donors could
mount a strong pp65-specific CD4+ (and to a lesser extent
CD8+) response upon in vitro stimulation, led the authors
to suggest that these individuals were previously exposed
to CMV but failed to mount a humoral immune response
[63]. We cannot exclude at this point this possibility nor
that TCR cross-reactivity with closely related herpes
viruses [66, 67] or with environmental antigens [68, 69] is
responsible for the detection of CMV-reactive cells in
CMV-seronegative hemodialysis patients. On the other
hand, we can reasonably exclude the possibility that
signals detected by IFN-γ ELISpot following 19 h of anti-
gen stimulation originate from CMV-specific naïve T cells
present in the PBMC population [70–72]. Indeed, al-
though antigen-specific naïve T cells can be primed
and expanded in vitro and in vivo [69, 72–78], the
vast majority of antigen-stimulated naïve T cells pro-
duce no IFN-γ and do not divide for the first ~3 days
of stimulation [69, 76, 79–82]. The higher proportion
of CMV-reactive cells in seronegative dialysis patients
in T-Track® CMV compared to QuantiFERON®-CMV
and iTAg™ MHC Tetramers supports the hypothesis
that IE-1-specific CD4+ T cells (and possibly CD8+ T
cells through cross-presentation) contribute to the
detected signals. On the other hand, the increased
proportion of IE-1-reactive cells over pp65-reactive
cells in CMV-seronegative patients supports the idea
of a recent exposure to CMV, as response to primary
infection is usually dominated by IE-1-reactive (pre-
dominantly CD8+) effector cells [6, 8–11]. Additional
experiments will be necessary to address these propo-
sitions. Whatever the mechanism involved in the gen-
eration of CMV-reactive effector cells in CMV-
seronegative patients, these observations raise the attract-
ive possibility that these individuals might have a protect-
ive immunity against CMV infection. Clearly, further
investigations are needed to address this possibility.
Altogether, our data suggest that T-Track® CMV exhibits a
performance superior to that of QuantiFERON®-CMV and
of iTAg™ MHC Tetramers, and possibly also superior to
that of CMV-IgG serology, for the detection of possible
immunity against CMV.
Conclusions
T-Track® CMV represents a highly standardized and
sensitive assay suitable for the monitoring of CMV-
specific cell-mediated immunity in end-stage renal fail-
ure patients, representative of patients prior to renal
transplantation. Further validation of T-Track® CMV in
multi-center clinical studies on kidney and allogeneic
stem cell transplant patients is currently on-going, to
evaluate its use for the risk assessment and prediction
of CMV-related clinical complications in transplant
recipients. In these situations, monitoring of CMV-
specific CMI could help physicians better define pa-
tient populations that would benefit from prophylactic
antiviral therapy, and assist the decision as to when
to withdraw prophylaxis safely. Reducing prophylactic
antiviral treatment would be beneficial in limiting both
treatment-related nephrotoxic side effects and costs.
Additional file
Additional file 1: Precision profiles of the specific response to IE-1 (A)
and pp65 (B) in T-Track® CMV. A coefficient of variation (CV) no higher
than 40% was used as a limit of acceptance of assay validity to determine
the respective limit of quantitation (LoQ). LoQ values determined at
CV = 40% for IE-1 (A) and pp65 (B) in the hemodialysis study (n = 124)
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Comparable LoQ values were obtained from T-Track® CMV assays performed
on PBMC from 45 healthy donors [38]. Based on these analyses, a technical
cut-off of 10 SFC / 200,000 PBMC was chosen. (PDF 334 kb)
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